168 related articles for article (PubMed ID: 16856932)
1. Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.
Gonzalez-Llano O; Jaime-Pérez J; Cantu-Rodríguez O; Mancias-Guerra C; Gutierrez-Aguirre H; Herrera-Garza J; Gomez-Almaguer D
Eur J Haematol; 2006 Oct; 77(4):341-4. PubMed ID: 16856932
[TBL] [Abstract][Full Text] [Related]
2. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in primary hemophagocytic lymphohistiocytosis.
Hamidieh AA; Pourpak Z; Hashemi S; Yari K; Fazlollahi MR; Movahedi M; Behfar M; Moin M; Ghavamzadeh A
Eur J Haematol; 2014 Apr; 92(4):331-6. PubMed ID: 24330187
[TBL] [Abstract][Full Text] [Related]
4. Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
Jillella AP; Shafer D; Klumpp TR; Emmons RV; Mangan KF
Am J Hematol; 2007 Jun; 82(6):419-26. PubMed ID: 17211845
[TBL] [Abstract][Full Text] [Related]
5. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity conditioning in unrelated donor cord blood transplantation for familial hemophagocytic lymphohistiocytosis.
Nishi M; Nishimura R; Suzuki N; Sawada A; Okamura T; Fujita N; Kanai R; Yano J; Adachi S; Yasumi T; Sato E; Yasutomo K; Ishii E; Ohga S
Am J Hematol; 2012 Jun; 87(6):637-9. PubMed ID: 22488407
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico.
Llano OG; Perez JC; Rodriguez OC; Guerra CM; Aguirre HG; Garza JL; Rodriguez-Romo L; Almaguer DG
Pediatr Hematol Oncol; 2008; 25(1):39-47. PubMed ID: 18231953
[TBL] [Abstract][Full Text] [Related]
8. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan.
Ohga S; Kudo K; Ishii E; Honjo S; Morimoto A; Osugi Y; Sawada A; Inoue M; Tabuchi K; Suzuki N; Ishida Y; Imashuku S; Kato S; Hara T
Pediatr Blood Cancer; 2010 Feb; 54(2):299-306. PubMed ID: 19827139
[TBL] [Abstract][Full Text] [Related]
10. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis.
Horne A; Janka G; Maarten Egeler R; Gadner H; Imashuku S; Ladisch S; Locatelli F; Montgomery SM; Webb D; Winiarski J; Filipovich AH; Henter JI;
Br J Haematol; 2005 Jun; 129(5):622-30. PubMed ID: 15916685
[TBL] [Abstract][Full Text] [Related]
11. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
12. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning.
Steiner M; Matthes-Martin S; Attarbaschi A; Minkov M; Grois N; Unger E; Holter W; Vormoor J; Wawer A; Ouachee M; Woessmann W; Gadner H
Bone Marrow Transplant; 2005 Aug; 36(3):215-25. PubMed ID: 15937510
[TBL] [Abstract][Full Text] [Related]
13. [Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].
Kuroki F; Goto H; Yanagimachi M; Kajiwara R; Fujii H; Isaki S; Takahashi H; Ikuta K; Yokota S
Rinsho Ketsueki; 2006 Jul; 47(7):639-44. PubMed ID: 16910574
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
[TBL] [Abstract][Full Text] [Related]
16. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
17. The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis.
Cooper N; Rao K; Goulden N; Webb D; Amrolia P; Veys P
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S47-50. PubMed ID: 18978744
[TBL] [Abstract][Full Text] [Related]
18. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP).
Cesaro S; Locatelli F; Lanino E; Porta F; Di Maio L; Messina C; Prete A; Ripaldi M; Maximova N; Giorgiani G; Rondelli R; Aricò M; Fagioli F
Haematologica; 2008 Nov; 93(11):1694-701. PubMed ID: 18768529
[TBL] [Abstract][Full Text] [Related]
20. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
